According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:
1. Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: A, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: B.
Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 55, which is 19 points higher than the general drug manufacturer industry average of 36.
GILD passed 20 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 29.06% over the past year, overperforming other general drug manufacturer stocks by 7 percentage points.
Gilead Sciences has an average 1 year
price target of $160.64, an upside of 21.06% from Gilead Sciences's current stock price of $132.69.
Gilead Sciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Gilead Sciences, 63.64% have issued a Strong Buy rating, 18.18% have issued a Buy, 18.18% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Bristol Myers Squibb Co (NYSE:BMY)
The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: B.
Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 48, which is 12 points higher than the general drug manufacturer industry average of 36.
BMY passed 17 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 14.62% over the past year, underperforming other general drug manufacturer stocks by -7 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $61.69, an upside of 7.51% from Bristol Myers Squibb Co's current stock price of $57.38.
Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Bristol Myers Squibb Co, 37.5% have issued a Strong Buy rating, 6.25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 6.25% have issued a Strong Sell.
3. Eli Lilly & Co (NYSE:LLY)
Eli Lilly & Co (NYSE:LLY) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: B.
Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 62, which is 26 points higher than the general drug manufacturer industry average of 36.
LLY passed 25 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 17.83% over the past year, underperforming other general drug manufacturer stocks by -4 percentage points.
Eli Lilly & Co has an average 1 year
price target of $1,246.21, an upside of 28.75% from Eli Lilly & Co's current stock price of $967.93.
Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 19 analysts covering Eli Lilly & Co, 68.42% have issued a Strong Buy rating, 26.32% have issued a Buy, 0% have issued a hold, while 5.26% have issued a Sell rating, and 0% have issued a Strong Sell.
